Legacy CG LLC Raises Stock Position in CVS Health Corporation $CVS

Legacy CG LLC grew its stake in CVS Health Corporation (NYSE:CVS) by 294.9% during the 3rd quarter, Holdings Channel reports. The firm owned 82,082 shares of the pharmacy operator’s stock after purchasing an additional 61,296 shares during the quarter. CVS Health makes up approximately 1.7% of Legacy CG LLC’s investment portfolio, making the stock its 27th largest position. Legacy CG LLC’s holdings in CVS Health were worth $6,188,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CVS. Avion Wealth increased its stake in CVS Health by 99.0% during the 2nd quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 142 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in CVS Health in the 2nd quarter valued at $30,000. Front Row Advisors LLC lifted its holdings in CVS Health by 436.5% in the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares in the last quarter. Finally, Roxbury Financial LLC boosted its stake in CVS Health by 78.3% during the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 202 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE CVS opened at $79.75 on Thursday. The stock has a fifty day simple moving average of $78.58 and a 200-day simple moving average of $73.69. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The stock has a market cap of $101.23 billion, a PE ratio of 209.86, a P/E/G ratio of 0.74 and a beta of 0.48. CVS Health Corporation has a twelve month low of $44.92 and a twelve month high of $85.15.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. During the same quarter in the prior year, the company posted $1.09 earnings per share. CVS Health’s revenue for the quarter was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be given a $0.665 dividend. The ex-dividend date of this dividend is Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. CVS Health’s payout ratio is presently 700.00%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CVS shares. Argus raised their price target on shares of CVS Health from $80.00 to $91.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Mizuho raised their target price on shares of CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Sanford C. Bernstein reissued a “market perform” rating and set a $91.00 price objective on shares of CVS Health in a research note on Tuesday. Finally, Barclays raised their target price on CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.86.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.